Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilonacept in Cold Contact Urticaria
NCT02171416Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2015
- Primary completion
- Feb 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cold urticaria comparing Rilonacept 160mg with Placebo (2 arms). Primary endpoint: Clinical signs and symptoms of CCU at 6 weeks. Started Jan 2015; status: completed.
02
Drugs
rilonacept
03
Conditions
cold urticaria
Beyond the preview
Go deeper on NCT02171416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171416.